Compugen (NASDAQ:CGEN) Posts Earnings Results, Beats Expectations By $0.02 EPS

Compugen (NASDAQ:CGEN) released its quarterly earnings results on Monday. The biotechnology company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02, FiscalAI reports. The company had revenue of $3.82 million for the quarter, compared to analysts’ expectations of $1.28 million. Compugen had a return on equity of 42.57% and a net margin of 47.56%. During the same quarter in the previous year, the company posted ($0.07) earnings per share.

Here are the key takeaways from Compugen’s conference call:

• COM701’s MAIA-ovarian trial is fully enrolled, with results expected by the end of Q1 2027. The 62-patient study will be assessed on the magnitude and durability of separation from placebo; management estimated the placebo arm’s median progression-free survival at about four months, while noting that comparator studies were not directly comparable.
• Rilvegostomig has a major clinical catalyst expected in H2 2027, when AstraZeneca anticipates high-level results from the phase III ARTEMIDE-Biliary01 trial. Compugen also cited phase II lung-cancer survival and tolerability data as supportive, though the phase III outcome remains uncertain.
• Gilead’s phase I program for GS-0321 continues in monotherapy and combination settings, but Compugen did not disclose the study’s current stage, evidence of biological activity, or a timeline for clinical data. The company is eligible for up to $758 million in additional milestones plus tiered royalties, contingent on program progress.
• Compugen ended September with $117.5 million in cash and investments and said its cash runway should extend into 2029, assuming no further inflows. Q3 net loss narrowed to $5.8 million from $7.0 million a year earlier, while R&D spending was unchanged at $5.8 million.
• Compugen introduced UnigenX, an expansion of its discovery platform aimed at finding tumor-associated antigens for targeted immune therapies such as T-cell engagers. The company sees potential to create pipeline and partnership opportunities, but did not give a timeline for new clinical candidates.

Compugen Trading Up 9.2%

Compugen stock opened at $2.14 on Tuesday. Compugen has a 52 week low of $1.43 and a 52 week high of $3.23. The stock has a market cap of $202.34 million, a price-to-earnings ratio of 5.63 and a beta of 2.85. The company’s 50-day moving average price is $2.24 and its two-hundred day moving average price is $2.29.

Analyst Upgrades and Downgrades

Several analysts recently commented on CGEN shares. HC Wainwright restated a “buy” rating and issued a $4.00 target price on shares of Compugen in a research report on Monday, October 12th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Compugen in a research report on Tuesday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, Compugen has an average rating of “Buy” and an average price target of $5.00.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is an Israeli clinical-stage biotechnology company focused on discovering and developing novel therapeutic and drug targets for cancer and other diseases. The company uses computational biology and artificial intelligence-based approaches to identify previously unrecognized biological mechanisms and translate them into potential medicines.

Compugen’s research has primarily centered on immuno-oncology, with an emphasis on regulating immune responses within the tumor microenvironment.